<DOC>
	<DOCNO>NCT00445601</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving gemcitabine directly bladder surgery may kill tumor cell . It yet know whether give gemcitabine directly bladder effective placebo treat bladder cancer . PURPOSE : This randomized phase III trial study gemcitabine see well work give directly bladder compare placebo surgery treat patient newly diagnose recurrent bladder cancer .</brief_summary>
	<brief_title>S0337 , Gemcitabine After Surgery Treating Patients With Newly Diagnosed Recurrent Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy single intravesical instillation gemcitabine hydrochloride v placebo immediately transurethral resection bladder tumor ( TURBT ) prevent recurrence 2 year patient grade 1 2 superficial transitional cell cancer bladder . Secondary - Compare whether single instillation intravesical gemcitabine hydrochloride improve time progression muscle invasive disease v placebo patient . - Compare qualitative quantitative toxicity regimens patient . - Compare whether treatment post-TURBT intravesical instillation gemcitabine v placebo result reduce long-term morbidity patient , define requirement fewer TURBTs , course traditional intravesical therapy , surveillance cystoscopies 4 year . Tertiary - Assess whether perform combination molecular and/or cytologic diagnostic marker test , include NMP-22 Bladder Chek BTA Stat every 3 month , predict recurrence accurately cystoscopy alone patient . OUTLINE : This randomize , double-blind , multicenter study . Patients stratify accord disease status ( first occurrence v recurrent disease ) number tumor site ( 1 v ≥ 2 ) . Patients randomize 1 2 treatment arm . All patient undergo transurethral resection bladder tumor . Within 3 hour , patient receive intravesical therapy accord randomized arm . - Arm I : Patients receive intravesical gemcitabine hydrochloride 1 hour . - Arm II : Patients receive intravesical placebo 1 hour . Urine collect baseline every 3 month 2 year research study include NMP-22 Bladder Chek BTA Stat test . After completion study treatment , patient follow every 3 month 2 year every 6 month 2 year . PROJECTED ACCRUAL : A total 340 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis newly diagnose recurrent transitional cell bladder cancer meeting follow criterion : Ta T1 primary tumor Grade 1 2 disease No 2 recurrence ( except index tumor ) within 18 month prior index tumor 's transurethral resection bladder tumor ( TURBT ) Index tumor postTURBT must meet following criterion : Ta T1 tumor without prior tumor situ , grade 3 ( high grade ) disease within 2 year prior index tumor TURBT , invasion muscularis propria ( stage ≥ T2 ) Grade 1 2 disease ( similar papillary urothelial neoplasm low malignant potential lowgrade bladder cancer ) Not candidate therapy TURBT ( e.g. , series instillation intravesical immunotherapy [ e.g. , BCG ] intravesical chemotherapy , cystectomy partial cystectomy ) Negative upper tract image study within 1 year ( 365 day ) prior study entry Imaging study may perform registration provide do prior TURBT day treatment No urothelial cancer prostate distal urethra ( urethra woman ) assess endoscopy Must negative urine culture ( less equal 10,000 col/mL , mixed floralikely contamination ) OR negative urine analysis infection AND negative nitrate reagent strip , ≤ 10 white blood cell count ( WBC ) /highpower field , rod organisms examination spun urine sediment OR automate visual reagent strip urinalysis negative leukocytes nitrate within past 28 day TURBT plan within next 28 day plan treatment within 3 hour TURBT PATIENT CHARACTERISTICS : Zubrod performance status 01 Not pregnant nursing Fertile patient must use effective contraception No prior malignancy except follow : Adequately treat basal cell squamous cell skin cancer In situ cervical cancer Adequately treat stage I II cancer patient complete remission Any cancer patient diseasefree 3 year PRIOR CONCURRENT THERAPY : See Disease Characteristics More 145 day since prior intravesical therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
</DOC>